Although there are many definitions of clinical trials, they are generally considered to be biomedical or health-related research studies in human beings that follow a pre-defined protocol. We have both interventional & observational types of clinical trials found on this site.
The purpose of this study is see if quality of life is improved in patients receiving oral hormone therapy compared to standard of care. The study will also compare survival rates between patients receiving oral hormone therapy and those receiving standard of care.
The purpose of this study is to observe clinical courses for long-term in patients with unprotected LMCA disease and to evaluate comparative results of medical treatment, coronary stenting with drug-eluting stents, and CABG for the treatment of an unprotected LMCA stenosis in the "real world" daily practice.
Medical imaging is one of the fastest growing sectors in health care and increases in
utilization underscore the need to ensure imaging technology is developed and used
effectively. Evaluation of the clinical and economic impact of such imaging lags behind the
technology development. Heart failure (HF)represents the final common pathway for most forms
of heart disease and morbidity and mortality remain high. There is a need to identify imaging
approaches that have a positive impact on therapy decisions, patient outcomes and costs. As
well as standard methods to evaluate new and emerging techniques to better test their
potential in a clinical management setting. The OVERALL OBJECTIVES of the IMAGE-HF trial are
1) to determine the impact of emerging imaging strategies, on relevant clinical outcomes and
decision making in patients with HF; 2) to establish standardization quality assurance (QA)
measures and central databases in order to achieve reliable outcome driven research; 3) to
apply this as a platform for evaluation of new and emerging imaging biomarkers in HF.
Project I-A: The PRIMARY OBJECTIVE OF AIMI-HF is to compare the effect of HF imaging strategies on the composite clinical endpoint of cardiac death, MI, resuscitated cardiac arrest and cardiac re-hospitalization (WHF, ACS, arrhythmia). Patients with an ischemic heart disease (IHD) etiology will follow HF imaging strategy algorithms according to the question(s) asked by the physicians (is there ischemia and/or viability), in agreement with their local practices for standard and alternative imaging.
Secondary objectives of AIMI-HF To compare the effect of HF imaging strategies on
1. The incidence of revascularization procedures (PCI, CABG)
2. LV remodeling: LV volumes, LVEF
3. HF symptoms, NYHA class
4. QOL (MLHFQ, the EQ5D)
5. The evolution of serum prognostic markers in HF (e.g. BNP, RDW, hs-cTnT, hs-CRP)
6. Health economics: Costs estimated through regression analysis and cost effectiveness assessed through decision modeling.
7. The safety of imaging tests measured by cumulative radiation, adverse reactions to imaging contrast agents and stress testing agents will also be determined.
8. The evolution of renal function (eGFR) and LV remodeling-associated biomarkers (e.g. PIIINP, OPN).